Format

Send to

Choose Destination
Int J Vasc Med. 2020 Mar 7;2020:4237204. doi: 10.1155/2020/4237204. eCollection 2020.

Is Nonmicronized Diosmin 600 mg as Effective as Micronized Diosmin 900 mg plus Hesperidin 100 mg on Chronic Venous Disease Symptoms? Results of a Noninferiority Study.

Author information

1
Hospital Albert Einstein (São Paulo-Brasil), R. Mauricio F Klabin 357/17, Vila Mariana, SP, Brazil 04120-020.
2
Instituto de Pós-Graduação Médica Carlos Chagas-Fundação Educacional Serra dos Órgãos-UNIFESO (Rio de Janeiro/Teresópolis-Brasil), Av. Alberto Torres 111, Teresópolis, RJ, Brazil 25964-004.
3
Fundação Educacional Serra dos Órgãos-UNIFESO (Teresópolis-Brasil), Av. Alberto Torres 111, Teresópolis, RJ, Brazil 25964-004.
4
Faculdade de Ciências Médicas, Universidade Estadual do Rio de Janeiro (UERJ) (Rio de Janeiro-Brazil), Av. N. Sra. De Copacapana, 664/206, Rio de Janeiro, RJ, Brazil 22050-903.
5
Fundação Educacional Serra dos Órgãos-UNIFESO (Teresópolis-Brasil), Rua Prefeito Sebastião Teixeira 400/504-1, Rio de Janeiro, RJ, Brazil 25953-200.
6
Instituto de Pós-Graduação Médica Carlos Chagas (Rio de Janeiro-Brazil), R. General Canabarro 68/902, Rio de Janeiro, RJ, Brazil 20271-200.
7
Department of Medicine, Rutgers New Jersey Medical School-USA, 185 S Orange Ave., Newark, NJ 07103, USA.
8
Hospital Universitário Pedro Ernesto, Universidade Estadual do Rio de Janeiro (UERJ) (Rio de Janeiro-Brazil), R. Hilário de Gouveia, 87/801, Rio de Janeiro, RJ, Brazil 22040-020.
9
Universidade Federal do Rio de Janeiro (UFRJ) (Rio de Janeiro-Brazil), Av. das Americas, 411/1613-2, Rio de Janeiro, RJ, Brazil 22631-000.
10
Laboratoire Innotech International, 22 Avenue Aristide Briand, 94110 Arcueil, France.

Abstract

Background:

Phlebotonics have beneficial effects on some symptoms related to chronic venous disease (CVD) of the lower limbs. The most commonly used one is diosmin, available in a pure semisynthetic form or as a micronized purified flavonoid fraction. Patients and Methods. The primary objective of this single-blind, randomized, parallel-group, prospective study was to assess the clinical noninferiority of nonmicronized diosmin 600 mg once daily (D-group) compared to micronized diosmin 900 mg plus hesperidin 100 mg once daily (D/H-group) over a 6-month treatment period. Adult patients with a symptomatic CVD of the lower limbs (C0-C3 grade; 20-60 mm on a 100 mm visual analog scale (VAS)) were included. The primary endpoint was the change (from baseline to last postbaseline value) of the intensity of the lower-limb symptoms on VAS.

Results:

114 patients (mean age, 44.4 years; women, 90.4%) were randomized in the per-protocol analysis (D-group, n = 57; D/H-group, n = 57; D/H-group, p < 0.0001) in the D-group and -22.8 mm (p < 0.0001) in the D-group and -22.8 mm (p < 0.0001) in the D-group and -22.8 mm (.

Conclusion:

Nonmicronized diosmin 600 mg was proven to have a noninferior efficacy compared to micronized diosmin 900 mg plus hesperidin 100 mg, associated with greater ease in swallowing the tablet.

Conflict of interest statement

I.B. and F.V. are employed by Laboratoire Innotech International. All other authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center